Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC

[Display omitted] Lung cancer is currently the highest morbidity and mortality malignancy all over the world. In the past, the treatment options available for patients with lung cancer were mainly chemotherapy and tyrosine kinase inhibitors, but after a period of treatment, cancer cells inevitably d...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biomedicine & pharmacotherapy 2020-07, Vol.127, p.109996-109996, Article 109996
Hauptverfasser:	Qu, Jialin, Jiang, Man, Wang, Li, Zhao, Deze, Qin, Kang, Wang, Yun, Tao, Junyan, Zhang, Xiaochun
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarker Biomarkers, Tumor - biosynthesis Biomarkers, Tumor - immunology Carcinoma, Non-Small-Cell Lung - drug therapy Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunotherapy NSCLC PD-1 PD-L1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!